论文部分内容阅读
目的观察联合免疫抑制(CIS)治疗重型再生障碍性贫血(SAA)的疗效。方法本院2004年6月-2008年9月应用抗胸腺细胞球蛋白联合环孢素对11例SAA患儿进行CIS治疗(CIS组),随访观察疗效,并将以往接受单一药物免疫抑制(SIS)治疗的19例SAA患儿作为对照(SIS组)。比较2组疗效及不良反应。结果 CIS组总有效率为81.8%(9/11例),明显高于SIS组。且经过积极预防及对症处理,药物不良反应轻微,不影响治疗。结论 CIS为治疗儿童SAA有效、安全的疗法,疗效明显高于SIS治疗。
Objective To observe the effect of combined immunosuppression (CIS) on severe aplastic anemia (SAA). METHODS: From June 2004 to September 2008, 11 patients with SAA were treated with CIS (CIS) with anti-thymocyte globulin and cyclosporine. The patients were followed up for treatment. The patients were treated with single-drug immunosuppression (SIS ) Treated 19 SAA children as a control (SIS group). The curative effect and side effects of two groups were compared. Results The total effective rate was 81.8% (9/11 cases) in CIS group, which was significantly higher than that in SIS group. And after active prevention and symptomatic treatment, adverse drug reactions minor, does not affect the treatment. Conclusion CIS is an effective and safe therapy for children with SAA, and its efficacy is obviously higher than that of SIS.